Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts

Food and Chemical Toxicology

Volumn 52, Issue , 2013, Pages 200-206

  Ye, Liang ^a   He, Jie ^a   Hu, Zhengping ^b   Dong, Qiuju ^a   Wang, Hongbo ^a   Fu, Fenghua ^a   Tian, Jingwei ^a  

^a YANTAI UNIVERSITY   (China)

^b Shandong International Biotechnology Park   (China)

Author keywords

Antitumor; Intraperitoneal administration; Liposome; Lipusu; Ovarian cancer; Toxicity

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREMOPHOR; HEMOGLOBIN; LACTATE DEHYDROGENASE; LIPOSOME; LIPUSU; PACLITAXEL; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BONE MARROW LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG HEART LEVEL; DRUG LYMPH LEVEL; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; ERYTHROCYTE COUNT; FEMALE; LEUKOPENIA; NONHUMAN; OVARY CANCER; PELVIS LYMPH NODE; RAT; THROMBOCYTE COUNT; TUMOR VOLUME; TUMOR XENOGRAFT;

ABDOMINAL PAIN; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW; DRUG DELIVERY SYSTEMS; FEMALE; HEART; INJECTIONS, INTRAPERITONEAL; LIPOSOMES; MICE; MYOCARDIUM; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; RATS; RATS, INBRED F344; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; RATTUS;

EID: 84871460772     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.11.004     Document Type: Article

References (32)

1. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., Burger R.A. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006, 354:34-43.
2. Bhoola S., Hoskins W.J. Diagnosis and management of epithelial ovarian cancer. Obstet. Gynecol. 2006, 107:1399-1410.
3. Birdi I., Angelini G.D., Bryan A.J. Biochemical markers of myocardial injury during cardiac operations. Ann. Thorac. Surg. 1997, 63:879-884.
4. Cabanes A., Briggs K.E., Gokhale P.C., Treat J.A., Rahman A. Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int. J. Oncol. 1998, 12:1035-1040.
5. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 2004, 351:2519-2529.
6. Chen Q., Zhang Q.Z., Liu J., Li L.Q., Zhao W.H., Wang Y.J., Zhou Q.H., Li L. Multi-center prospective randomized trial on paclitaxel liposome and traditional taxol in the treatment of breast cancer and non-small-cell lung cancer. Zhonghua Zhong Liu Za Zhi 2003, 25:190-192.
7. Cuong N.V., Hsieh M.F. Molecular targeting of liposomal nano-particles to lymphatic system. Curr. Cancer Drug Tar. 2011, 11:147-155.
8. Feki A., Berardi P., Bellingan G., Major A., Krause K.H., Petignat P., Zehra R., Pervaiz S., Irminger-Finger I. Dissemination of intraperitoneal ovarian cancer: discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model. Crit. Rev. Oncol. Hematol. 2009, 72:1-9.
9. Forssen E.A., Tokes Z.A. Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. Cancer Treat. Rep. 1983, 67:481-484.
10. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42:419-436.
11. Madhavan S., Northfelt D.W. Lack of vesicant injury following extravasation of liposomal doxorubicin. J. Natl. Cancer Inst. 1995, 87:1556-1557.
12. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs 2008, 68:771-789.
13. Markman M. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer. Cancer J. 2009, 15:105.
14. Markman M., Rowinsky E., Hakes T., Reichman B., Jones W., Lewis J.L., Rubin S., Curtin J., Barakat R., Phillips M., et al. Phase I trial of intraperitoneal taxol: a gynecoloic oncology group study. J. Clin. Oncol. 1992, 10:1485-1491.
15. Marupudi N.I., Han J.E., Li K.W., Renard V.M., Tyler B.M., Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin. Drug Saf. 2007, 6:609-621.
16. Parker R.J., Hartman K.D., Sieber S.M. Lymphatic absorption and tissue disposition of liposome-entrapped [14C]adriamycin following intraperitoneal administration to rats. Cancer Res. 1981, 41:1311-1317.
17. Parker R.J., Priester E.R., Sieber S.M. Effect of route administration and liposome entrapment on the metabolism and disposition of adriamycin in the rat. Drug Metab. Dispos. 1982, 10:499-504.
18. Phillips W.T., Medina L.A., Klipper R., Goins B. A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodes. J. Pharmacol. Exp. Ther. 2002, 303:11-16.
19. Rosa P., Clementi F. Absorption and tissue distribution of doxorubicin entrapped in liposomes following intravenous or intraperitoneal administration. Pharmacology 1983, 26:221-229.
20. Rose G.S., Tocco L.M., Granger G.A., DiSaia P.J., Hamilton T.C., Santin A.D., Hiserodt J.C. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am. J. Obstet. Gynecol. 1996, 175:593-599.
21. Sadzuka Y., Hirama R., Sonobe T. Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy. Toxicol. Lett. 2002, 126:83-90.
22. Sankaranarayanan R., Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best. Pract. Res. Clin. Obstet. Gynaecol. 2006, 20:207-225.
23. Sharma A., Mayhew E., Bolcsak L., Cavanaugh C., Harmon P., Janoff A., Bernacki R.J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer 1997, 71:103-107.
24. Sharma A., Mayhew E., Straubinger R.M. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 1993, 53:5877-5881.
25. Sharma A., Sharma U.S., Straubinger R.M. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett. 1996, 107:265-272.
26. Sharma A., Straubinger R.M., Ojima I., Bernacki R.J. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J. Pharm. Sci. 1995, 84:1400-1404.
27. Working P.K., Newman M.S., Sullivan T., Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J. Pharmacol. Exp. Ther. 1999, 289:1128-1133.
28. Xie Y., Bagby T.R., Cohen M.S., Forrest M.L. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opin. Drug Deliv. 2009, 6:785-792.
29. Yang A.Z., Li J., Xu H.J., Chen H.Y. A study on antitumor effect of liposome encapulated paclitaxel in vivio and in vitro. Bull. Chin. Cancer 2006, 15:862-864.
30. Zahedi P., Yoganathan R., Piquette-Miller M., Allen C. Recent advances in drug delivery strategies for treatment of ovarian cancer. Expert Opin. Drug Deliv. 2012, 9:567-583.
31. Zhang Q., Huang X.E., Gao L.L. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed. Pharmacother. 2009, 63:603-607.
32. Zhou W., Weng G.Y., Chen W.Z., Zhuang Y., Fu X.Y., Cheng G. Tissue distribution of paclitaxel liposome in rats. Chin. Pharm. J. 2005, 40:1402-1404.